Background: 1. . The incidence and mortality of colon cancer are high in China and in the world. 2. . The treatment of many patients in the real world is not standardized, and there are problems such as over-treatment or under-treatment. To explore the adjuvant treatment of colon cancer in the Chinese population, this study will retrospectively analyze real-world data on adjuvant therapy for colon cancer in Chinese patients after radical surgery. The purpose of research: 1. . Current status of adjuvant therapy for stage II-III colon cancer in the real world: chemotherapy regimen, chemotherapy time, efficacy, safety, etc. 2. . Comparison of efficacy and safety of different adjuvant chemotherapy time (\<3 months vs. \>=3 months) in high-risk stage II and III colon cancer patients in the real world 3. . Comparison of efficacy and safety of different adjuvant chemotherapy regimens (XELOX vs. FOLFOX) in high-risk stage II and III colon cancer patients in the real world
Study Type
OBSERVATIONAL
Enrollment
20,000
Jiangsu Province People Hospital
Nanjing, Jiangsu, China
RECRUITINGChanghai Hospital of Shanghai
Shanghai, Shanghai Municipality, China
RECRUITINGSAHZU
Hangzhou, Zhejinag, China
RECRUITINGPercentage of patients with chemotherapy regimen for adjuvant therapy after stage II and stage III colon cancer
Percentage of patients with chemotherapy regimen for adjuvant therapy after stage II and stage III colon cancer
Time frame: From patients after stage II and stage III colon cancer radical resection to until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months.
Percentage of patients with different chemotherapy time for adjuvant therapy for stage II and stage III colon cancer
Percentage of patients with different chemotherapy time for adjuvant therapy for stage II and stage III colon cancer
Time frame: From patients after stage II and stage III colon cancer radical resection to until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months.
Percentage of Participants with treatment-related Adverse Events as Assessed by CTCAE v4.0 for adjuvant therapy for stage II and stage III colon cancer
Percentage of Participants with treatment-related Adverse Events as Assessed by CTCAE v4.0 for adjuvant therapy for stage II and stage III colon cancer
Time frame: From patients after stage II and stage III colon cancer radical resection to until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.